Intelligence Feed event · Macro · 2026-10-12

    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for Encaleret

    Question

    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for Encaleret

    Direct answer

    BridgeBio announced top-line outcomes from its Phase 3 CALIBRATE trial evaluating encaleret for autosomal dominant hypocalcemia type 1. The data showed 91% of encaleret-treated patients normalized blood PTH levels compared to zero in the standard care cohort. Symptom improvements reached 100% in the active arm against 46% in conventional therapy. Following these results, the FDA accepted the company's regulatory submission for review.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-12
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for Encaleret”, revision 1, evidence through 2026-10-12. https://marketontology.com/market-events/2026-10-12/bridgebio-reports-positive-phase-3-calibrate-trial-results-for-encaleret-93a37f

    MACRO
    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for Encaleret
    BridgeBio announced top-line outcomes from its Phase 3 CALIBRATE trial evaluating encaleret for autosomal dominant hypocalcemia type 1. The data showed 91% of encaleret-treated patients normalized blood PTH levels compared to zero in the standard care cohort. Symptom improvements reached 100% in the active arm against 46% in conventional therapy. Following these results, the FDA accepted the company's regulatory submission for review.
    BBIO
    Impact
    68
    OCT 12
    SIG
    92%
    BBIO
    BridgeBio Reports Positive Phase 3 CALIBRATE Trial Results for Encaleret
    BridgeBio announced top-line outcomes from its Phase 3 CALIBRATE trial evaluating encaleret for autosomal dominant hypocalcemia type 1. The data showed 91% of encaleret-treated patients normalized blood PTH levels compared to zero in the standard care cohort. Symptom improvements reached 100% in the active arm against 46% in conventional therapy. Following these results, the FDA accepted the company's regulatory submission for review.
    → Regulatory acceptance and 91% primary endpoint efficacy establish commercial exclusivity potential in ADH1 for BBIO.
    Impact
    BridgeBio announced top-line outcomes from its Phase 3 CALIBRATE trial evaluating encaleret for autosomal dominant hypocalcemia type 1. The data showed 91% of encaleret-treated patients normalized blood PTH levels compared to zero in the standard care cohort. Symptom improvements reached 100% in the active arm against 46% in conventional therapy. Following these results, the FDA accepted the company's regulatory submission for review.
    Affected
    BBIO
    Transmission
    Regulatory acceptance and 91% primary endpoint efficacy establish commercial exclusivity potential in ADH1 for BBIO.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    BBIObiotech clinical validation and regulatory progressUp1-5dPositive Phase 3 CALIBRATE trial results and FDA regulatory filing acceptance announced.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    BBIOUpdisagreed65.75 2026-10-12-3.73%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month